Inclusion Criteria:  Written informed consent obtained from the patient prior to performing any protocol-related procedures, including screening evaluations. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures. Female or male, Age ≥ 18 years at time of study entry. Performance Status: 0 or 1. Clinical evidence of NMIBC based on cystoscopy and proven histologically of papillary tumors. Histologically-confirmed pTa Grade 3 or pT1 Grade 3 bladder cancer patients relapsing without muscle invasion. Negative sterile Urine cytobacteriological testing at baseline (T0). Consent to use a contraception method for at least 30 days after administration of 89Zr-girentuximab. Patient has valid health insurance.  Exclusion Criteria:  Patient with urinary incontinence. Known hypersensitivity to girentuximab. Exposure to any experimental diagnostic or therapeutic drug within 30 days prior the date of planned administration of 89Zr-girentuximab Exposure to any radiopharmaceutical within 30 days (corresponding to 10 half-lives of Zr-89) prior to the administration of 89Zr-girentuximab Patients suffering from a bladder cancer at stage pT2, pT3 or pT4 Serious non-malignant disease that may interfere with the objectives of the study or with the safety or compliance of the patient; as judged by the investigator Concomitant cancer in the past 5 years except cutaneous cancers (except melanoma) and in situ carcinoma Prior chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy), immunotherapy within 21 days of 89Zr-girentuximab administration Patients with known human immunodeficiency viruses (HIV), Hepatitis B virus (HBV) and Hepatitis C Virus (HCV) infections, Pregnant or likely to be pregnant or nursing patient. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study Persons deprived of their liberty, under a measure of safeguard of justice, under guardianship or placed under the authority of a guardian.